Strides Pharma Receives USFDA Form 483 with 5 Observations

Strides Pharma discloses completion of a routine USFDA cGMP inspection at its Bangalore flagship facility from May 12-20, 2026.
The USFDA issued a Form 483 containing five observations at the conclusion of the inspection.
The company will respond to the observations within the stipulated timeframe and inform exchanges of further updates.
This is a regulatory disclosure under SEBI Listing Regulation 30 regarding a compliance event.